PD-L1 expression and clinical outcomes with targeted therapy
A recent study published in Clinical Cancer Research analysed tumour [...]
ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib
The results from the following study were presented at the [...]
Current role of mTOR inhibitors in metastatic kidney cancer
The following video interview with Dr Eric Jonasch, from the [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer
Cabozantinib significantly improves overall survival in previously treated patients with [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer
Results from a phase 1 clinical trial looking at CB-839, [...]
Quality of life outcomes similar for cabozantinib and everolimus
Data from the phase 3 METEOR trial published in the Journal [...]
Cabozantinib more effective than everolimus for treatment of kidney cancer bone metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in people [...]
